Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelvic Irradiation With or Without Cisplatin in Recurrent Uterine Corpus Carcinoma
NCT00492778Phase 2Unknown
- Sponsor
- GOG Foundation
- Start
- Feb 2008
- Primary completion
- Dec 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of Cisplatin micelle injection (HA132) in endometrial cancer (EC) (2 arms), sponsored by GOG Foundation. Primary endpoint: Progression-Free Survival up to 128 months. Status: unknown.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00492778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492778.